Dianthus Therapeutics, Inc. (DNTH)
82.37
-0.06
(-0.07%)
USD |
NASDAQ |
Oct 09, 16:00
83.00
+0.63
(+0.76%)
After-Hours: 20:00
Dianthus Therapeutics Enterprise Value : 3.628B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 3.628B |
| October 08, 2026 | 3.631B |
| October 07, 2026 | 3.766B |
| October 06, 2026 | 3.794B |
| October 05, 2026 | 3.939B |
| October 02, 2026 | 3.948B |
| October 01, 2026 | 3.954B |
| September 30, 2026 | 3.939B |
| September 29, 2026 | 3.891B |
| September 28, 2026 | 3.927B |
| September 25, 2026 | 3.967B |
| September 24, 2026 | 4.085B |
| September 23, 2026 | 4.235B |
| September 22, 2026 | 4.504B |
| September 21, 2026 | 4.401B |
| September 18, 2026 | 4.419B |
| September 17, 2026 | 4.656B |
| September 16, 2026 | 4.731B |
| September 15, 2026 | 4.856B |
| September 14, 2026 | 5.016B |
| September 11, 2026 | 4.934B |
| September 10, 2026 | 4.774B |
| September 09, 2026 | 4.980B |
| September 08, 2026 | 5.095B |
| September 04, 2026 | 5.038B |
| Date | Value |
|---|---|
| September 03, 2026 | 5.024B |
| September 02, 2026 | 4.936B |
| September 01, 2026 | 4.957B |
| August 31, 2026 | 4.902B |
| August 28, 2026 | 4.914B |
| August 27, 2026 | 5.227B |
| August 26, 2026 | 5.184B |
| August 25, 2026 | 5.258B |
| August 24, 2026 | 5.146B |
| August 21, 2026 | 5.203B |
| August 20, 2026 | 5.115B |
| August 19, 2026 | 5.345B |
| August 18, 2026 | 5.446B |
| August 17, 2026 | 5.409B |
| August 14, 2026 | 5.469B |
| August 13, 2026 | 5.120B |
| August 12, 2026 | 5.274B |
| August 11, 2026 | 5.060B |
| August 10, 2026 | 5.241B |
| August 07, 2026 | 5.083B |
| August 06, 2026 | 5.138B |
| August 05, 2026 | 5.279B |
| August 04, 2026 | 5.164B |
| August 03, 2026 | 4.924B |
| July 31, 2026 | 4.974B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Verastem, Inc. | 706.21M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.22M |
| Revenue (Quarterly) | 0.761M |
| Total Expenses (Quarterly) | 50.98M |
| EPS Diluted (Quarterly) | -0.8962 |
| Gross Profit Margin (Quarterly) | 85.94% |
| Profit Margin (Quarterly) | -6.60K% |
| Earnings Yield | -5.04% |
| Normalized Earnings Yield | -5.040 |